Cue Biopharma (CUE) – Research Dossier

Q3 2025 (press release, unaudited, in thousands):

Q1 2025 (press release, unaudited, in thousands):

Historical comparison – Q3 2023 (10-Q, in thousands):

• Cash and cash equivalents: $54,691
• Marketable securities: $24,675

This shows a substantial reduction in cash and marketable securities from late 2023 to mid-/late-2025, partly offset by the April 2025 follow-on offering (about 20M dollars gross), the Boehringer Ingelheim upfront (12M dollars) and collaboration revenue from multiple partners.

Net loss as a rough proxy for burn (9M 2025):

• 9M 2025 net loss was 28.2 million dollars, which is approximately 3.1 million dollars per month on average (not identical to cash burn but directionally similar).
• Cash plus marketable securities as of September 30, 2025 were 18.7 million dollars (11.7M cash plus 7.0M marketable securities).

Using net loss as a coarse burn proxy suggests a runway on the order of roughly six months from September 30, 2025 if no new capital or additional major upfront payments were received. Actual runway could be somewhat longer or shorter depending on:

• non-cash charges,
• changes in R&D spend (for example, trial completion or restructuring), and
• timing of collaboration payments (for example, Boehringer milestones or ImmunoScape upfront tranches).

The company continues to flag going-concern risk in its SEC filings and emphasizes the need for additional capital to continue operations beyond roughly 12 months.

Note: This runway estimate is approximate and based on reported net loss, not detailed cash flow from operations.

This is a non-exhaustive summary reconstructed from accessible filings; for precise share counts, pricing and full legal terms, the underlying 8-K, S-3 and prospectus supplements should be consulted.

8.1 Selected financing events

• October 1, 2021 – ATM program: Cue entered into an Open Market Sale Agreement with Jefferies LLC, establishing an “at-the-market” equity program allowing the company to sell common stock into the market over time.
• November 14, 2022 – Registered direct / PIPE: A Securities Purchase Agreement and related Registration Rights Agreement were executed, enabling a sizable fundraising via a combination of registered direct and private placements. The transaction contributed materially to share count expansion and cash resources entering 2023.
• 2023 – Ongoing ATM usage and loan amendments: The company amended its loan agreement with Silicon Valley Bridge Bank and continued to have the ATM facility available under an S-3 shelf filed in May 2023, giving management flexibility to raise equity opportunistically.
• April 2025 – Underwritten follow-on offering (~20M dollars gross): In Q1 2025 communications, Cue reported raising approximately 20 million dollars in gross proceeds via an underwritten public offering, contributing to a sharp increase in weighted average shares from about 49.5 million to about 74.3 million between Q1 2024 and Q1 2025.
• 2025 – Collaboration-related and non-dilutive funding:
  • Boehringer Ingelheim collaboration (CUE-501): 12 million dollars upfront plus milestones and royalties; non-equity, non-dilutive cash from April 2025.
  • ImmunoScape collaboration: 15 million dollars upfront (staggered) and a 40% equity stake in ImmunoScape, with Cue as the licensor; no new Cue shares were issued as part of this deal.

8.2 Overall pattern

The combination of persistent operating losses, ongoing clinical development costs and limited existing revenue has led management to rely repeatedly on equity financing, both via discrete offerings (such as November 2022 and April 2025) and ongoing ATM capacity, while also layering in non-dilutive income via collaborations (Boehringer, ImmunoScape, historical Ono and other deals).

From an investor’s perspective, this pattern underscores a meaningful dilution history, with basic share count roughly doubling from around 50 million to around 100 million between 2023 and late 2025, and a continued need for new capital unless future partnerships or clinical success unlock substantially larger non-dilutive funding sources.

9.1 Key executives

• Usman “Oz” Azam, M.D. – President and CEO (since September 2025):
  • Appointed CEO effective September 29, 2025, with over 25 years of global drug development and leadership experience.
  • Prior roles include CEO of Inspirna, Inc. (clinical-stage oncology), CEO of Empyrean Neuroscience (genetic engineering for CNS disorders), President and CEO of Tmunity Therapeutics (CAR-T cell therapies for solid tumors) and Global Head of Cell and Gene Therapies at Novartis, involved in the launch of the first FDA-approved CAR-T therapy for hematologic cancers.
  • Has also held senior roles at Pfizer, Aspreva, Johnson & Johnson and GSK.
  • His appointment is explicitly tied to Cue’s autoimmune pivot and the plan to advance CUE-401 and partnered programs through clinical development.
• Daniel Passeri – Former CEO, now Strategic Advisor:
  • Long-time CEO through 2023–2024 and into Q1 2025.
  • Led the company through its IPO, initial development of the Immuno-STAT platform and early collaborations.
  • Transitioned to Strategic Advisor concurrent with Dr. Azam’s appointment.
• Kerri-Ann Millar – Chief Financial Officer: Named in 10-K and 10-Q filings as CFO, responsible for financial reporting, capital structure management and financing strategy.

9.2 Governance and ownership

• Board of Directors: Chaired by Pasha Sarraf, M.D., Ph.D., who in 2025 publicly framed CUE-401 as having the potential to become a “Keytruda for autoimmune disease” – a strong internal expression of ambition for the asset, but still very early and unproven in humans.
• Insider ownership: Precise percentages are disclosed in the proxy statement and 10-K. Historically, executives, directors and key founders hold a single-digit to low double-digit aggregate stake, influenced by stock grants and vesting.
• Governance issues: No high-profile governance scandals are apparent in recent filings. Risk factor sections emphasize going-concern risk, dependency on partnerships and potential conflicts in collaborations (for example, exclusivity with Merck or LG Chem).

10.1 Historical oncology collaborations

• Merck (Merck & Co., Inc.):
  • Collaboration focused on validating the Immuno-STAT platform in oncology settings, leveraging Merck’s checkpoint inhibitor expertise.
  • Includes exclusivity provisions that restrict certain R&D activities; details are described in 10-K risk factor sections.
• LG Chem (Asia rights):
  • 2018 collaboration granting LG Chem rights to CUE-101 and other IL-2-based CUE-100 series assets in Asia.
  • Structure involves upfront payments, milestones and royalties; specific amounts are in the original agreement filings.
• Ono Pharmaceutical:
  • Collaboration and option agreement that provided collaboration revenue in 2023–2024.
  • Terminated in March 2025; Cue recognized residual revenue and regained rights, as reflected in Q1 2025 results.

10.2 Autoimmune and platform deals

• Boehringer Ingelheim (CUE-501 / CUE-500 series):
  • Scope: CUE-501, a lead CUE-500 series bispecific designed to redirect anti-viral memory T cells to pathogenic B cells in autoimmune disease.
  • Headline financial terms: 12 million dollars upfront; up to about 345 million dollars in potential milestones; tiered royalties on net sales (rates not fully disclosed).
  • Strategic importance: Validates the CUE-500 platform in autoimmunity and provides non-dilutive funding and potential downstream economics.
• ImmunoScape (Seed-and-Boost TCR-T in solid tumors):
  • Scope: Combine ImmunoScape’s tumor-specific TCR-T cells (“Seed”) with CUE-100 series Immuno-STAT boosters (“Boost”) to enhance in-vivo expansion and persistence of engineered T cells in solid tumors.
  • Headline financial terms: 15 million dollars upfront (10 million in Q4 2025; 5 million in November 2026); 40% equity stake in ImmunoScape for Cue; high single-digit royalties on net sales.
  • Strategic importance: Extends the CUE-100 series into cell therapy without Cue itself needing to build a full TCR-T infrastructure and supports the “platform licensing” strategy for oncology while Cue prioritizes internal spend on autoimmune programs.

This section summarizes publicly visible, non-professional commentary; it is anecdotal and should not be treated as a data source for fundamentals.

11.1 Stocktwits and retail sentiment

• Bullish narrative (typical themes):
  • Emphasis on CUE-101 combination data (50% ORR, long mOS) and its perceived superiority to historical Keytruda monotherapy in first-line HPV+ HNSCC.
  • Excitement about the autoimmune pivot, positioning CUE-401 as a potential tolerance-inducing therapy in diseases with high unmet need.
  • Optimism around non-dilutive funding from Boehringer and ImmunoScape upfronts and the possibility of additional large-pharma partnerships.
• Bearish narrative:
  • Concern over going-concern language and the history of dilutive financing (ATM programs and secondary offerings).
  • Skepticism about Cue’s ability to fund late-stage trials in oncology and autoimmune indications without further share issuance.
  • Doubts about the path from promising Phase 1 data to actual regulatory approval and commercial traction in a crowded immuno-oncology and autoimmune landscape.
• Neutral / trader-style comments: Focus on short-term price swings, volume spikes around news and technical patterns rather than fundamentals.

11.2 Reddit, X (Twitter) and other forums

• Some users frame Cue as a “platform option”: if either CUE-101 or CUE-401/CUE-501 succeeds, the upside could be meaningful; if not, the company remains high risk due to limited cash and small market capitalization.
• Others are wary of small-cap biotech risk: a combination of trial failure and funding challenges can be destructive regardless of platform promise.

These are opinions of non-professional traders and commentators. They can be useful to gauge sentiment and positioning but are not a substitute for reading SEC filings, company press releases and clinical trial documents.

This section outlines qualitative scenarios without probabilities, price targets or recommendations.

12.1 Constructive / success-oriented scenario

• CUE-401 progresses successfully into clinical trials, showing acceptable safety and early signals of restoring tolerance in a targeted autoimmune indication and attracting interest from potential partners or acquirers.
• CUE-501 and the CUE-500 series advance under Boehringer, with positive preclinical or early clinical data and milestone payments starting to flow.
• CUE-101 finds a viable development path (through partnerships or larger trials) in HPV+ HNSCC or related settings, confirming that the Phase 1 data can be replicated in larger cohorts.
• The ImmunoScape Seed-and-Boost program continues to generate encouraging preclinical and early translational data, supporting a broader platform story in solid tumors.
• Cue secures additional non-dilutive or less-dilutive capital (for example, more partnerships, milestone triggers or carefully structured financing), reducing reliance on frequent equity issuance.

12.2 Mixed / volatile scenario

• CUE-401 enters the clinic but delivers only modest or delayed signals; further dose-finding, patient selection or combination strategies are needed.
• CUE-101 remains scientifically interesting but development slows or becomes heavily partner-dependent; no near-term registrational study is launched.
• Collaboration milestones from Boehringer or ImmunoScape are slower than expected, producing episodic but not continuous cash inflows.
• The company remains reliant on equity markets, leading to ongoing dilution even as the platform remains credible scientifically.

12.3 Negative / failure-oriented scenario

• Clinical results for CUE-401 or other autoimmune assets reveal safety issues or insufficient efficacy, leading to program delays, terminations or portfolio reprioritization.
• CUE-101/CUE-102 fail to show sufficient advantage over standard of care in larger or more rigorous studies, making it harder to justify further investment or attract partners.
• The biotech funding environment remains difficult, making capital raising more costly or unavailable, while going-concern warnings persist or intensify.
• Partners reduce their level of engagement (for example, shelving partnered programs), diminishing expected milestone and royalty streams.
• In this scenario, Cue’s options could narrow rapidly, with focus potentially shifting toward restructuring, asset sales or strategic alternatives.

12.4 Platform-survival / asset-monetization scenario

• Individual programs have mixed outcomes, but the platform intellectual property and know-how remain attractive.
• Cue increasingly out-licenses technology (for example, Immuno-STAT modules for specific antigens or autoimmune targets) to multiple partners.
• The company functions more as a technology licensor than as a full pipeline developer.

13.1 Key risk categories

• Scientific and clinical risk: Early-stage clinical data, especially in small cohorts, may not translate into robust benefit in larger trials. The complexity of immune modulation in both cancer and autoimmune disease carries a risk of unexpected toxicities or insufficient efficacy.
• Regulatory risk: Regulatory agencies may require larger or longer studies, strict safety monitoring or may not agree with proposed endpoints in tolerance-focused autoimmune studies. Cross-trial comparisons used in positioning CUE-101 versus historical Keytruda monotherapy will not substitute for randomized data in regulatory decision-making.
• Execution risk: Cue must coordinate multiple programs (CUE-101, CUE-102, CUE-401, CUE-501 and the ImmunoScape Seed-and-Boost initiative) with limited staff and capital. Enrollment in selected populations (for example, HLA-A*0201-positive, HPV16+ HNSCC or WT1+ cancers) can be slower or more expensive.
• Financing and dilution risk: The historical pattern of frequent equity raises and going-concern language indicates that dilution risk remains significant, especially if markets are risk-off. Debt covenants may limit flexibility, and higher interest rates can increase financing costs.
• Partner dependency and collaboration risk: Financial and strategic expectations from Boehringer Ingelheim, ImmunoScape, LG Chem, Merck and others may not materialize on the expected timeline, or at all. Termination of prior partnerships, such as Ono, shows that not all collaborations persist.
• Governance and concentration risk: Transition from a long-time CEO to a new leader is a major change; success depends on alignment between management, the board and shareholders. Insider and institutional concentration can amplify volatility around good or bad news.

13.2 Open questions a cautious analyst might track

• CUE-401 clinical timing: When will an IND be filed, and in which autoimmune indication or indications will CUE-401 first be tested?
• CUE-401 clinical goalposts: What constitutes a meaningful early-phase signal in terms of biomarkers and clinical outcomes (for example, disease activity scores or relapse rates) in the chosen disease?
• CUE-101 next steps: Will Cue or a partner commit to a larger, potentially registrational CUE-101 trial in HPV+ HNSCC, and if so, what will the design look like (first-line versus second-line, comparator arm, geographic scope)?
• Balance sheet strategy: How will Cue address ongoing going-concern disclosures—through additional partnerships, cost reductions or further equity/debt financing?
• Boehringer and ImmunoScape milestones: What concrete preclinical or early-clinical milestones might trigger near-term payments, and are any of them guided for the next 12–24 months?
• Competitive pipeline in autoimmune IL-2/Treg space: How does CUE-401 compare mechanistically and in preclinical data to other emerging Treg-inducing or IL-2-based therapies being advanced by larger companies?
• Regulatory stance on tolerance-inducing drugs: How open are regulators to mechanistic biomarkers and surrogate endpoints in autoimmune indications targeted by CUE-401?
• IP and patent coverage: Are there upcoming patent expirations or key freedom-to-operate questions around pMHC-IL-2 fusion designs?
• Partner optionality for oncology assets: If Cue focuses internally on autoimmunity, will additional partners step in to co-fund or acquire rights to CUE-101 and CUE-102, or will these assets stagnate?
• Macro and financing environment: How sensitive is Cue’s ability to continue development to biotech capital market conditions (for example, small-cap risk appetite and interest rates)?